HAEMATOPOIETIC STEM CELL TRANSPLANTATION TO PATIENTS WITH MULTIPLE SCLEROSIS
Abstract
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system leading to severe neurological deficits. Current MS treatment consists in using immunomodulatory agents aimed to reduce a rate of relapses. However, these agents are usually insufficient to treat the chronic neurological disability. The haematopoietic stem cell transplantation (HSCT) is a perspective method of MS treatment. Our review of the literature presents the information on the clinical trials of MS HSCT.
About the Authors
O. E. Gichkun
V. I. Shumakov Federal Research Center of Transplantology and Artificial Organs
Russian Federation
Russian Federation
E. B. Yaroshenko
V. I. Shumakov Federal Research Center of Transplantology and Artificial Organs
Russian Federation
Russian Federation
A. O. Shevchenko
V. I. Shumakov Federal Research Center of Transplantology and Artificial Organs
Russian Federation
Russian Federation
References
1. Frohman, E. M. Multiple sclerosis the plaque and its pathogenesis / E. M. Frohman, M. K. Racke, C. S. Raine // N. Engl. J. Med. – 2006. – N 354. – P. 942–955.
2. Рассеянный склероз / под ред. Е. И. Гусева, И.А. Завалишина, А.Н. Бойко. – М.: Реал Тайм, 2011. – 528 с.
3. Dendrou, C. A. Immunopathology of multiple sclerosis / C. A. Dendrou, L. Fugger, M. A. Friese // Nat. Rev. Immunol. – 2015. – Vol. 15, N 9. – Р. 545–558. – doi: 10.1038/nri3871. Epub. 2015 Aug. 7.
4. Riedhammer, C. Antigen presentation, autoantigens, and immune regulation in Multiple sclerosis and other autoimmune diseases / C. Riedhammer, R. Weissert // Front Immunol. – 2015. – Vol. 17, N 6. – Р. 322. – doi: 10.3389/fim-mu.2015.00322. eCollection 2015.
5. Atkins, H. L. Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned / H. L. Atkins, M. S. Freedman // Neurotherapeutics. – 2013. – Vol. 10, N 1. – Р. 68–76. – doi: 10.1007/s13311-012-0162-5.
6. Ribatti, D. The fundamental contribution of Robert A. Good to the discovery of the crucial role of thymus in mammalian immunity / D. Ribatti // Immunology. – 2006. – Vol. 119, N 3. – Р. 291–295.
7. Complications of allogeneic hematopoietic stem cell transplantation / K. Arnaout [et al.] // Cancer Invest. – 2014. – Vol. 32, N 7. – P. 349–362. – doi: 10.3109/07357907.2014.919301. Epub. 2014 June 5.
8. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation / D. M. Karussis [et al.] // J. Clin. Invest. – 1993. – N 92. – Р. 765–772.
9. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation / J. A. Snowden [et al.] // Bone Marrow Transplant. – 2012. – N 47. – Р. 770–790.
10. Transplantation for autoimmune diseases in north and south america: a report of the Center for International Blood and Marrow Transplant Research / M. C. Pasquini [et al.] // Biol. Blood Marrow Transplant. – 2012. – N 18. – Р. 1471–1478.
11. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study / A. Fassas [et al.] // Bone Marrow Transplant. – 1997. – Vol. 20, N 8.– P. 631–638. – doi:10.1038/sj. bmt.1700944.
12. Autologous stem cell transplantation in progressive multiple sclerosis – an interim analysis of efficacy / A. Fassas [et al.] // J. Clin. Immunol. – 2000. – Vol. 20, N 1. – P. 24–30.
13. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study / A. Fassas [et al.] // J. Neurol. – 2002. – Vol. 249, N 8. – P. 1088–1097. – doi:10.1007/s00415-002-08007.
14. High dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis / T. Kozak [et al.] // Bone Marrow Transplant. – 2000. – Vol. 25, N 5. – P. 525-531. – doi:10.1038/sj.bmt.1702180.
15. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring / H. Openshaw [et al.] // Biol. Blood Marrow Transplant. – 2000. – Vol. 6, N 5A. – P. 563–575.
16. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores / R. K. Burt [et al.] // Blood. – 2003. – Vol. 102, N 7. – P. 2373–2378. – doi:10.1182/blood-2003-03-0877.
17. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis / R. A. Nash [et al.] // Blood. – 2003. – Vol. 102, N 7. – P. 2364–2372. – doi:10.1182/blood-2002-12-3908.
18. Clinical and MRI outcome after autologous hematopoietic stem cell transplantation iMS / A. Saiz [et al.] // Neurology. – 2004. – Vol. 62, N 2. – P. 282–284.
19. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life / R. Saccardi [et al.] // Blood. – 2005. – Vol. 105, N 6. – P. 2601–2607. – doi:10.1182/ blood-2004-08-3205.
20. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database / R. Saccardi [et al.] // Mult. Scler. – 2006. – Vol. 12, N 6. – P. 814–823.
21. Intense T-cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis / J. P. Samijn [et al.] // J. Neurol. Neurosurg. Psychiatry. – 2006. – Vol. 77, N 1. – P. 46–50. – doi:10.1136/jnnp.2005.063883.
22. Clinical outcomes after autologous haematopoietic stem cell transplantation in patients with progressive multiple sclerosis / J. Xu [et al.] // Chin. Med. J. (Engl.). – 2006. – Vol. 119, N 22. – P. 1851–1855.
23. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis / Y. L. Shevchenko [et al.] // Exp. Hematol. – 2008. – Vol. 36, N 8. – P. 922–928. – doi:10.1016/j.ex-phem.2008.03.001.
24. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing remitting multiple sclerosis: a phase I/II study / R. K. Burt [et al.] // Lancet Neurol. – 2009. – Vol. 8, N 3. – P. 244–253. – doi:10.1016/S1474-4422(09)70017-1.
25. Fagius, J. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation / J. Fagius, J. G. Lundgren // Oberg. Mult. Scler. – 2009. – Vol. 15, N 2. – P. 229–237. – doi:10.1177/1352458508096875.
26. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple scle- rosis: a single center 10-year experience / E. Krasulova [et al.] // Mult. Scler. – 2010. – Vol. 16, N 6. – P. 685–693. – doi:10.1177/1352458510364538.
27. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/ horse ATG and CY/ rabbit ATG / N. Hamerschlak [et al.] // Bone Marrow Transplant. – 2010. – Vol. 45, N 2. – P. 239–48. – doi:10.1038/bmt.2009.127.
28. Long-term results of stem cell transplantation for MS: a single-center experience / A. Fassas [et al.] // Neurology. – 2011. – Vol. 76, N 12. – P. 1066–1070. – doi:10.1212/WNL.0b013e318211c537. Outcome of HSCT in MS patients after a median follow-up of 11 years.
29. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis / Y. L. Shevchenko [et al.] // Exp. Hematol. – 2012. – Vol. 40, N 11. – P. 892–898. – doi:10.1016/j.exphem.2012.07.003.
30. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results / J. D. Bowen [et al.] // Bone Marrow Transplant. – 2012. – Vol. 47, N 7. – P. 946–951. – doi:10.1038/bmt.2011.208.
31. Autologous haematopoietic stem cell transplantation with an intermediaten intensity conditioning regimen in multiple sclerosis: the Italian multi-center experience / G. L. Mancardi [et al.] // Mult. Scler. – 2012. – Vol. 18, N 6. – P. 835–842. – doi:10.1177/1352458511429320. Italian study of autologous HSCT in MS with BEAM/ATG conditioning regimen.
32. Long-term efficacy оf autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China / B. Chen [et al.] // Neurol. Sci. – 2012. – Vol. 33, N 4. – P. 881–886. – doi:10.1007/s100720110859-y.
33. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience / J. Burman [et al.] // J. Neurol. Neurosurg. Psychiatry. – 2014. – doi:10.1136/jnnp-2013-307207.
34. Havrdova, E. Aggressive multiple sclerosis – is there a role for stem cell transplantation? / E. Havrdova // J. Neurol. – 2005. – N 252 (Suppl. 3). – P. III34–III37.
35. Italian GITMO-NEURO Intergroup on Autologous Stem Cell Transplantation. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study / L. Roccatagliata [et al.] // Mult. Scler. – 2007. – N 13. – P. 1068–1070.
36. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients / P. A. Muraro [et al.] // J. Exp. Med. – 2005. – N 201. – P. 805–816.
37. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial / G. L. Mancardi [et al.] // Neurology. – 2015. – Vol. 84, N 10. – P. 981–988. – doi: 10.1212/WNL.0000000000001329. Epub. 2015 Feb. 11.
Review
For citations:
Gichkun O.E., Yaroshenko E.B., Shevchenko A.O. HAEMATOPOIETIC STEM CELL TRANSPLANTATION TO PATIENTS WITH MULTIPLE SCLEROSIS. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2016;(2):110-117. (In Russ.)
Views: 400
Email this article 